Lipid disorder and intrahepatic renin–angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease

Liver International

Volumn 36, Issue 10, 2016, Pages 1525-1534

  Wu, Yu ^a   Ma, Kun L ^a   Zhang, Yang ^a   Wen, Yi ^a   Wang, Gui H ^a   Hu, Ze B ^a   Liu, Liang ^a   Lu, Jian ^a   Chen, Pei P ^a   Ruan, Xiong Z ^b   Liu, Bi C ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

extracellular matrix; LDLr pathway; lipid disorder; non alcoholic fatty liver disease; renin angiotensin system

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 1 RECEPTOR; APOLIPOPROTEIN E; CHOLESTEROL; COLLAGEN TYPE 1; FIBRONECTIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TELMISARTAN; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; ENDOPLASMIC RETICULUM; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE TRANSLOCATION; GOLGI COMPLEX; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT GENE; LIPID STORAGE; LIVER CELL; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION;

EID: 84986260078     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13131     Document Type: Article

References (33)

1. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372–84.
2. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134–40.
3. Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91: 4753–61.
4. Van Rooyen DM, Larter CZ, Haigh WG, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011; 141: 1393–403.
5. Zhao L, Chen Y, Tang R, et al. Inflammatory stress exacerbates hepatic cholesterol accumulation via increasing cholesterol uptake and de novo synthesis. J Gastroenterol Hepatol 2011; 26: 875–83.
6. Zheng S, Hoos L, Cook J, et al. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 2008; 584: 118–24.
7. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am 2008; 37: 635–6.
8. Takahashi N, Li F, Hua K, et al. Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab 2007; 6: 506–12.
9. Ran J, Hirano T, Adachi M. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 2004; 287: E227–32.
10. Yvan-Charvet L, Even P, Bloch-Faure M, et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 2005; 54: 991–9.
11. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008; 102: 488–96.
12. Morris EM, Rector RS, Thyfault JP, Ibdah JA. Mitochondria and redox signaling in steatohepatitis. Antioxid Redox Signal 2011; 15: 485–504.
13. Kudo H, Yata Y, Takahara T, et al. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int 2009; 29: 988–96.
14. Elks CM, Francis J. Central adiposity, systemic inflammation, and the metabolic syndrome. Curr Hypertens Rep 2010; 12: 99–104.
15. Pereira RM, dos Santos RA, da Costa Dias FL, Teixeira MM, Simoese Silva AC. Renin-angiotensin system in the pathogenesis of liver fibrosis. World J Gastroenterol 2009; 15: 2579–86.
16. Day CP, James OFW. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114: 842–5.
17. Ni J, Ma KL, Wang CX, et al. Activation of renin-angiotensin system is involved in dyslipidemia-mediated renal injuries in apolipoprotein E knockout mice and HK-2 cells. Lipids Health Dis 2013; 12: 49.
18. Ma KL, Ni J, Wang CX, et al. Interaction of RAS activation and lipid disorders accelerates the progression of glomerulosclerosis. Int J Med Sci 2013; 10: 1615–24.
19. Gamble W, Vaughan M, Kruth HS, Avigan J. Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells. J Lipid Res 1978; 19: 1068–70.
20. Nickenig G, Sachinidis A, Michaelsen F, et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95: 473–8.
21. Li D, Saldeen T, Romeo F, Mehta JL. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation 2000; 102: 1970–6.
22. Dima A, Marinescu AG, Dima AC. Non-alcoholic fatty liver disease and the statins treatment. Rom J Intern Med 2012; 50: 19–25.
23. Paschos P, Tziomalos K. Nonalcoholic fatty liver disease and the renin-angiotensin system: implications for treatment. World J Hepatol 2012; 4: 327–31.
24. Bataller R, Sancho-Bru P, Gines P, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003; 125: 117–25.
25. Wei Y, Clark SE, Thyfault JP, et al. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. Am J Pathol 2009; 174: 1329–37.
26. Wei Y, Clark SE, Morris EM, et al. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol 2008; 49: 417–28.
27. Warner FJ, Lubel JS, McCaughan GW, Angus PW. Liver fibrosis: a balance of ACEs? Clin Sci (Lond) 2007; 113: 109–18.
28. Liu J, Ma KL, Zhang Y, et al. Activation of mTORC1 disrupted LDL receptor pathway: a potential new mechanism for the progression of non-alcoholic fatty liver disease. Int J Biochem Cell Biol 2015; 61C: 8–19.
29. Lu J, Mehta JL. LOX-1: a critical player in the genesis and progression of myocardial ischemia. Cardiovasc Drugs Ther 2011; 25: 431–40.
30. Gurley SB, Coffman TM. The renin-angiotensin system and diabetic nephropathy. Semin Nephrol 2007; 27: 144–52.
31. Kalaitzidis R, Bakris GL. Effects of angiotensin II receptor blockers on diabetic nephropathy. J Hypertens Suppl 2009; 27: S15–21.
32. Reiser J, Mundel P. Dual effects of RAS blockade on blood pressure and podocyte function. Curr Hypertens Rep 2007; 9: 403–8.
33. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009; 15: 942–54.